Invitrogen has regularly reported pro forma results which exclude acquisition related amortization and other costs. First quarter pro forma net income was $50.9 million, or $0.88 per share, compared with pro forma net income in the first quarter of 2004 of $35.7 million, or $0.62 per share. Pro forma net income and pro forma earnings per share increased 43% and 42%, respectively.
“The Effect of Contingently Convertible Debt on Diluted Earnings per Share”
Reconciliations between Invitrogen's results and pro forma results for the periods reported are presented in the attached tables with information also presented on the Company's Investor Relations web page at www.invitrogen.com.
Performance Highlights
-- Record revenues in both BioDiscovery and BioProduction
-- Generated $63.0 million in cash from operating activities for the quarter
-- Closed the acquisitions of Dynal Biotech ASA and Zymed Laboratories, Inc.
-- Increased guidance for the year
Conference Call and Webcast Today at 5:00 PM Eastern
The Company will discuss its first quarter 2005 results, as well as updated 2005 guidance on its conference call at 5:00 pm Eastern Time today. Additional details regarding the call and webcast are included later in this release.
First Quarter Review
Greg Lucier, Invitrogen's Chairman and CEO, commented: "We are pleased with the Company's performance during the first quarter. We exceeded our targets for both revenues and pro forma earnings per share, and have raised our annual guidance as a result. In addition, we are still on track to meet our organic growth rate projection of 6-8% for the full year. More than 200,000 catalogs, which include thousands of new, innovative products, have been shipped to our customers worldwide. We believe this will have a meaningful impact on growth for the balance of the year. We remain enthusiastic about our ability to execute in 2005 and are confident that Invitrogen will continue to deliver consistent value and returns to our customers and shareholders."
First quarter 2005 revenue growth of 10% included approximately 2% from favorable changes in foreign currency exchange rates and 4% from acquisitions. Revenue growth of 6% in BioDiscovery includes a 2% contribution from favorable foreign currency exchange rates and a 1% contribution from acquisitions. BioProduction revenues increased approximately 16% in the first quarter principally related to the acquired BioReliance business and continuing demand for cell culture products. The effects of currency and the acquisition of BioReliance, contributed 2% and 9%, respectively to the growth of the BioProduction segment.
First quarter 2005 gross margin was 62%, compared to 56% in the first quarter of 2004. BioDiscovery gross margin increased to 72% in the first quarter of 2005 from 70% in the first quarter of 2004, as product mix has migrated toward higher value, proprietary product offerings. BioProduction gross margin increased to 48% from 46% in the comparable quarter of 2004, as a result of a migration toward higher value cell culture products and the improvement in margins at BioReliance.
Operating income was 16% of revenues in the first quarter of 2005 versus 10% in the first quarter of 2004. Operating income before acquisition related amortization and other costs was 26% of revenues in the first quarter of 2005, consistent with the first quarter of 2004.
Cash flows from operating activities were $63.0 million and capital expenditures were $11.9 million during the first quarter of 2005. Free cash flow, defined as cash from operating activities less capital expenditures, was $51.1 million for the first quarter.
Included in other income for both GAAP and Pro Forma results is a gain of $2.7 million related to the sale of an equity investment and a gain of $2.2 million associated with the revaluation of a short-term foreign currency denominated intercompany loan. In addition, included in the GAAP results is a gain of $21.0 million, related to the hedging activity associated with the acquisition of Dynal.
Subsequent to the end of the quarter, Invitrogen purchased approximately $125 million of its 2 1/4% Convertible Subordinated Notes Due 2006. This transaction reduces the Company's fully-diluted shares outstanding by approximately 1 million shares for fiscal 2005. This transaction was financed with a short term bridge loan, which is secured by the Company's short-term marketable securities. The bridge loan facility provides up to $250 million, approximately half of which was drawn to finance the repurchase.
2005 Outlook
Guidance is revised upward to reflect the fact that the Company exceeded its guidance during the first quarter and to incorporate the effect of the bond repurchase detailed earlier in the release. The Company projects that revenue for fiscal 2005 will be in a range of approximately $1,179 million to $1,195 million. Pro forma earnings per share are expected to range from $3.50 to $3.53. The Company will provide further detail on its business outlook on the conference call today.
Investor Day
Invitrogen will be hosting an investor day on June 16, 2005 in Carlsbad, CA at the Company's headquarters. The meeting will begin at 8AM and will conclude at noon. Further details will be provided in a future press release.
Conference Call and Webcast Details
The Company will discuss its financial and business results as well as its business outlook on its conference call at 5 pm Eastern Time today. This conference call will contain forward-looking information. The conference call will include a discussion of "non-GAAP financial measures" as that term is defined in Regulation G. For actual results, the most directly comparable GAAP financial measures and information reconciling these non-GAAP financial measures to the company's financial results determined in accordance with GAAP, as well as other material financial and statistical information to be discussed on the conference call will be posted at the Company's Investor Relations website at www.invitrogen.com.
The conference call will be webcast live over the Company's investor relations website at www.invitrogen.com and will be archived at the site for one month.
To listen to the live conference call, please dial (888) 396-2298 (domestic) or (617) 847-8708 (international) and use passcode 82774482. A replay of the call will be available for one week by dialing (888) 286-8010 (domestic) and (617) 801-6888 (international). The passcode for the replay is 80637794.
About Invitrogen
Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California and conducts business in more than 70 countries around the world. The company globally employs approximately 4,500 scientists and other professionals and had revenues of more than $1 billion in 2004. For more information about Invitrogen, visit the company's web site at www.invitrogen.com.
Statement Regarding Use of Non-GAAP Measures
We regularly have reported pro forma results for net income and earnings per share in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.
Our financial results under GAAP include substantial non-cash charges and tax benefits related to acquired businesses. Our pro forma calculations of net income and earnings per share, excluding acquisition related amortization and other similar costs, are limited because they do not reflect the entirety of our business costs. However, management believes that the pro forma presentation is a useful supplemental disclosure to investors as it provides an indication of the profitability and cash flows of the combined businesses apart from the initial, sunk cost of the acquisition. Management believes that this information is therefore useful to investors in analyzing and assessing our past and future operating performance.
In addition to the non-cash charges above, we exclude from our pro forma results the costs to integrate our acquired businesses or significant costs to restructure existing businesses as well as related tax benefits. Management views these costs as not indicative of the profitability or cash flows of its ongoing or future operations and excludes these costs as a supplemental disclosure to assist investors in evaluating and assessing our past and future operational performance.
We encourage investors to carefully consider our results under GAAP, as well as our pro forma disclosures and the reconciliation between these presentations to more fully understand our business. Reconciliations between GAAP results and pro forma results are presented on the following pages.
Safe Harbor Statement
Certain statements contained in this press release and in today's conference call are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Such statements include, but are not limited to statements regarding Invitrogen's: 1) financial projections, including revenue and pro forma earnings per share; 2) momentum in 2005; 3) ability to generate new products that will accelerate scientific research and our future growth; 4) integration of acquired businesses; and 5) ability to combine technologies of acquired businesses. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to a) the Company's ability to identify promising technology and, new product development opportunities; b) the Company's ability to identify and implement measures to effect cost savings and efficiency improvements; and c) the Company's ability to identify acquisitions and organic growth opportunities that will position it to serve growing markets, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.
INVITROGEN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)(unaudited) For the Three
Months
Ended March 31,
-------------------
2005 2004
--------- ---------
Revenues $277,081 $251,324
Cost of revenues 106,422 109,339
--------- ---------
Gross profit 170,659 141,985
--------- ---------
Operating expenses:
Sales and marketing 48,480 45,454
General and administrative 30,004 27,023
Research and development 21,241 15,748
Purchased intangibles amortization 25,901 28,228
Purchased in-process research and development 1,200 -
--------- ---------
Total operating expenses 126,826 116,453
--------- ---------
Operating income 43,833 25,532
--------- ---------
Other income (expense):
Interest income 5,876 5,854
Interest expense (7,258) (9,481)
Loss on early retirement of debt - (6,775)
Other income (expense), net 25,673 32
--------- ---------
Total other income and expense, net 24,291 (10,370)
--------- ---------
Income before provision for income taxes 68,124 15,162
Income tax provision (21,050) (4,653)
--------- ---------
Net income $47,074 $10,509
========= =========
Earnings per common share:
Basic $0.91 $0.20
========= =========
Diluted $0.82 $0.19
========= =========
Weighted average shares used in per share
calculation:
Basic 51,455 51,697
Diluted 60,229 55,005
INVITROGEN CORPORATION
RECONCILIATION OF GAAP TO PRO FORMA STATEMENTS OF INCOME(1)
(in thousands, except per share data) For the Three Months
Ended March 31, 2005
---------------------------------
(unaudited) GAAP Adjustments Pro Forma
--------- ------------ ----------
Revenues $277,081 $- $277,081
Cost of revenues 106,422 (692)(2)(3) 105,730
--------- ------------ ----------
Gross profit 170,659 692 171,351
--------- ------------ ----------
Gross margin 62% 62%
Operating expenses:
Sales and marketing 48,480 (60) (3) 48,420
General and administrative 30,004 (12) (3) 29,992
Research and development 21,241 (216) (3) 21,025
Purchased intangibles amortization 25,901 (25,901) (4) -
Purchased in-process research and
development 1,200 (1,200) (5) -
--------- ------------ ----------
Total operating expenses 126,826 (27,389) 99,437
--------- ------------ ----------
Operating income 43,833 28,081 71,914
Operating margin 16% 26%
Total other income and expense, net 24,291 (20,123) (6) 4,168
--------- ------------ ----------
Income before provision for income
taxes 68,124 7,958 76,082
Income tax provision (21,050) (4,133) (7) (25,183)
--------- ------------ ----------
Net income $47,074 $3,825 $50,899
Add back interest expense
subordinated debt, net of tax 2,382 - 2,382
--------- ------------ ----------
Numerator for diluted earnings per
share $49,456 $ 3,825 $ 53,281
========= ============ ==========
Earnings per common share:
Basic $0.91 $0.99
========= ==========
Diluted $0.82 $0.88
========= ==========
Weighted average shares used in per
share calculation:
Basic 51,455 - 51,455
Diluted 60,229 - 60,229
(in thousands, except per share data) For the Three Months
Ended March 31, 2004
----------------------------------
(unaudited) GAAP Adjustments Pro Forma
-------- --------------- ---------
Revenues $251,324 $- $251,324
Cost of revenues 109,339 (10,382)(2)(3) 98,957
---------- --------------- ---------
Gross profit 141,985 10,382 152,367
---------- --------------- ---------
Gross margin 56% 61%
Operating expenses:
Sales and marketing 45,454 (62) (3) 45,392
General and administrative 27,023 (6) (3) 27,017
Research and development 15,748 (211) (3) 15,537
Purchased intangibles amortization 28,228 (28,228) (4) -
Purchased in-process research and
development - - -
---------- --------------- ---------
Total operating expenses 116,453 (28,507) 87,946
---------- --------------- ---------
Operating income 25,532 38,889 64,421
Operating margin 10% 26%
Total other income and
expense, net (10,370) - (10,370)
---------- --------------- ---------
Income before provision
for income taxes 15,162 38,889 54,051
Income tax provision (4,653) (13,725) (7) (18,378)
---------- --------------- ---------
Net income $10,509 $25,164 $35,673
Add back interest expense
subordinated debt, net of tax 189 2,134 (8) 2,323
---------- --------------- ---------
Numerator for diluted
earnings per share $10,698 $27,298 $37,996
========== =============== =========
Earnings per common share:
Basic $0.20 $0.69
========== =========
Diluted $0.19 (9) $0.62
========== =========
Weighted average shares
used in per share calculation:
Basic 51,697 - 51,697
Diluted 55,005(9) 6,006(8) 61,011
(1) The Company has regularly reported pro forma results which
exclude the amortization of purchased intangibles, amortization of
inventory revaluation costs on products sold that were previously
written-up under purchase accounting rules and in-process research and
development to provide a supplemental comparison of results of
operations.
(2) Add back costs for purchase accounting inventory revaluations
of $0.6 million and $10.3 million for the three months ended March 31,
2005 and 2004, respectively.
(3) Add back deferred compensation amortization totaling $0.4
million and $0.4 million for the three months ended March 31, 2005 and
2004, respectively, related to stock option plans assumed in business
combinations.
(4) Add back amortization of purchased intangibles.
(5) Add back in-process research and development.
(6) Add back gain on foreign currency transaction, net of loss on
sale of investments, used for business acquisitions.
(7) The Company's effective income tax rate used in the
calculation of pro forma net income differs from the effective income
tax rate applied for GAAP purposes. The effective income tax rate on
GAAP pre-tax income is lower because the expenses included in GAAP
pre-tax income, but excluded from pro forma pre-tax income, produce a
tax benefit in a taxing jurisdiction having a higher tax rate than the
Company's overall average income tax rate.
(8) Pro forma diluted earnings per share includes the potential
dilution from the 2006 and 2024 Convertible Subordinate Debt, and,
using the as-if-converted method, which assumes that the debt was
converted at the beginning of the period presented with related
interest expense, net of tax, added back to the numerator and shares
from the assumed conversion of the debt added to the denominator.
(9) The Company has restated 2004 diluted weighted average shares
and earnings per share to reflect the impact of Emerging Issues Task
Force (EITF) Issue No. 04-8, "The Effect of Contingently Convertible
Debt on Diluted Earnings per Share," on its 1 1/2% Convertible Senior
Notes due 2024 and 2% Convertible Senior Notes due 2023.
INVITROGEN CORPORATION
EBITDA INFORMATION
For the Three
Months Ended
March 31,
-----------------
(in thousands)(unaudited) 2005 2004
-------- --------
Operating income reported under GAAP $43,833 $25,532
Add back in-process research and development and
merger-related amortization 28,081 38,889
Add back depreciation 9,247 8,866
Add back amortization of non merger-related deferred
compensation 1,174 522
Add back amortization of all other intangible assets 996 679
-------- --------
EBITDA $83,331 $74,488
======== ========
INVITROGEN CORPORATION
BUSINESS SEGMENT HIGHLIGHTS
FOR THE THREE MONTHS ENDED MARCH 31, 2005 AND 2004
(in Bio- Bio- Unallocated(1) Total
thousands)(unaudited) Discovery Production
-----------------------------------------------
Segment Results for the Three Months Ended March 31, 2005
---------------------------------------------------------
Revenues from external
customers $162,351 $114,730 $- $277,081
===============================================
Gross profit 116,155 55,198 (694) 170,659
-----------------------------------------------
Gross margin 72% 48% 62%
Selling,
administrative and
R&D 71,132 28,304 289 99,725
Merger-related
amortization and in-
process research
and development - - 27,101 27,101
-----------------------------------------------
Operating income 45,023 26,894 (28,084) 43,833
Operating margin 28% 23% 16%
Segment Results for the Three Months Ended March 31, 2004
---------------------------------------------------------
Revenues from external
customers $152,673 $98,651 $- $251,324
===================================== =========
Gross profit 107,283 45,084 (10,382) 141,985
-----------------------------------------------
Gross margin 70% 46% 56%
Selling,
administrative and
R&D 63,856 24,090 279 88,225
Merger-related
amortization - - 28,228 28,228
-----------------------------------------------
Operating income 43,427 20,994 (38,889) 25,532
Operating margin 28% 21% 10%
(1) Unallocated items for the three months ended March 31, 2005
and 2004 include costs for purchase accounting inventory revaluations
of $0.6 million and $10.3 million, amortization of purchased
intangibles of $25.9 million and $28.2 million, amortization of
deferred compensation of $0.4 million and $0.4 million, and in-process
research and development of $1.2 million and $0, respectively, which
are not allocated by management for purposes of analyzing the
operations, since they are principally non-cash or other costs
resulting primarily from business restructuring or purchase accounting
that are separate from ongoing operations.
INVITROGEN CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands) March December
31, 31,
2005 2004
----------- -----------
ASSETS (unaudited)
Current assets:
Cash and investments $1,025,043 $983,381
Trade accounts receivable, net of allowance
for doubtful accounts 182,295 165,754
Inventories 127,293 122,787
Deferred income taxes 27,971 31,866
Prepaid expenses and other current assets 33,696 28,440
----------- -----------
Total current assets 1,396,298 1,332,228
Property and equipment, net 225,541 222,193
Goodwill 1,466,117 1,424,671
Intangible assets, net 437,384 440,182
Long-term investments 40,925 109,088
Other assets 87,368 85,973
----------- -----------
Total assets $3,653,633 $3,614,335
=========== ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of long-term obligations $1,803 $12,390
Accounts payable, accrued expenses and other
current liabilities 164,533 183,285
Income taxes 19,081 510
----------- -----------
Total current liabilities 185,417 196,185
Long-term debt 1,319,561 1,319,315
Pension liabilities 15,086 15,307
Deferred income tax liability 156,055 153,716
Other long-term liabilities 12,947 16,561
Stockholders' equity 1,964,567 1,913,251
----------- -----------
Total liabilities and stockholders' equity $3,653,633 $3,614,335
=========== ===========
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
Email 
